SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
DNO ASA (DTNOF) , forward earnings yield 18.98%. PEG 0.67 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
- VALUE (0/100, Fail) — the composite valuation score falls below the 60/100 threshold required to pass.
- Forward P/E 5.3
- PEG Ratio 0.67 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
Overall SharesGrow Score: 34/100 with 0/7 criteria passed.
SharesGrow 7-Criteria Score
✗
HEALTH
33/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — DTNOF
Valuation Multiples
P/E (TTM)0.0
Forward P/E5.3
PEG Ratio0.67
Forward PEG0.67
P/B Ratio0.00
P/S Ratio1.30
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-0.05
Forward EPS (Est.)$0.37
Book Value / Share$0.00
Revenue / Share$1.51
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Forward Earnings Yield18.98%
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$-0.03 |
$201.8M |
$-35.3M |
-17.5% |
| 2017 |
$0.47 |
$347.4M |
$495M |
142.5% |
| 2018 |
$0.34 |
$829.3M |
$354.3M |
42.7% |
| 2019 |
$0.07 |
$971.3M |
$73.5M |
7.6% |
| 2020 |
$-0.29 |
$614.9M |
$-285.9M |
-46.5% |
| 2021 |
$0.21 |
$1B |
$203.9M |
20.3% |
| 2022 |
$0.39 |
$1.38B |
$384.9M |
28% |
| 2023 |
$0.02 |
$667.5M |
$18.6M |
2.8% |
| 2024 |
$-0.03 |
$666.8M |
$-27.1M |
-4.1% |
| 2025 |
$-0.05 |
$1.47B |
$-25.94M |
-1.8% |
